Free Trial
Investment Research Tools for the A.I. EraStart My Trial

Theralase Technologies (CVE:TLT) Trading 2.5% Higher - Here's What Happened

Written by MarketBeat
October 11, 2025
Theralase Technologies logo with Medical background

Key Points

  • Theralase Technologies Inc. shares increased by 2.5% to C$0.21, with a trading volume surge of 138% compared to the average session.
  • The company has a market capitalization of C$52.70 million and a negative price-to-earnings ratio of -11.39, indicating its current unprofitability.
  • Theralase specializes in developing light-activated compounds and patented super-pulsed laser technology for treating cancer, bacteria, and chronic pain.
  • Five stocks we like better than Theralase Technologies.

Shares of Theralase Technologies Inc. (CVE:TLT - Get Free Report) traded up 2.5% on Friday . The company traded as high as C$0.21 and last traded at C$0.21. 231,910 shares traded hands during mid-day trading, an increase of 138% from the average session volume of 97,386 shares. The stock had previously closed at C$0.20.

Theralase Technologies Stock Performance

The stock has a market capitalization of C$52.70 million, a price-to-earnings ratio of -11.39 and a beta of -0.23. The firm has a fifty day moving average of C$0.20 and a 200 day moving average of C$0.20. The company has a debt-to-equity ratio of 14.85, a current ratio of 1.91 and a quick ratio of 3.40.

About Theralase Technologies

(Get Free Report)

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Theralase Technologies Right Now?

Before you consider Theralase Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theralase Technologies wasn't on the list.

While Theralase Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own: Fall 2025 Cover
10 Best Stocks to Own: Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report
Like this article? Share it with a colleague.